LEADER 01169nam--2200373---450-
001 990001134680203316
005 20050517114607.0
010   $a3-16-147620-4
035   $a000113468
035   $aUSA01000113468
035   $a(ALEPH)000113468USA01
035   $a000113468
100   $a20030306d20012001km-y0enga50------ba
101 0 $ager
102   $aDE
105   $ay|||z|||001yy
200 1 $aGott als Geheimnis der Welt$eZur Begründung der Theologie des Gekreuzigten im Streit zwischen Theismus und Atheismus$fEberhard Jüngel
205   $a7. Auflage um ein Vorwort ergänzt
210   $aTübingen$cMohr Siebeck$d2001
215   $aXXI, 564 p.$d24 cm.
606 0 $aDio
676   $a231
700  1$aJÜNGEL,$bEberhard$0397236
801  0$aIT$bsalbc$gISBD
912   $a990001134680203316
951   $aII 2 2341(XIV 1600)$b167584 L.M.$cXIV$d00097258
959   $aBK
969   $aUMA
979   $aMARIA$b10$c20030306$lUSA01$h1239
979   $aPATRY$b90$c20040406$lUSA01$h1718
979   $aRENATO$b90$c20041108$lUSA01$h1200
979   $aCOPAT6$b90$c20050517$lUSA01$h1146
996   $aGott als Geheimnis der Welt$9980257
997   $aUNISA

LEADER 01790oam  2200493   450 
001 9910715017103321
005 20210402093054.0
035   $a(CKB)5470000002507836
035   $a(OCoLC)1224541481$z(OCoLC)1227256921
035   $a(EXLCZ)995470000002507836
100   $a20201130d2020      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFairness in Orphan Drug Exclusivity Act $ereport (to accompany H.R. 4712)
210  1$a[Washington, D.C.] :$c[U.S. Government Publishing Office],$d[2020]
215   $a1 online resource (11 pages)
225 1 $aReport / 116th Congress, 2d session, House of Representatives ;$v116-572
300   $a"November 16, 2020."
320   $aIncludes bibliographical references.
517   $aFairness in Orphan Drug Exclusivity Act 
606   $aDrug development$xEconomic aspects$zUnited States
606   $aBuprenorphine$xTherapeutic use$zUnited States
606   $aOrphan drugs$xGovernment policy$zUnited States
606   $aDrugs$xPrices$xGovernment policy$zUnited States
606   $aDrugs$xLaw and legislation$zUnited States
606   $aOrphan drugs$zUnited States
606   $aRare diseases$zUnited States
608   $aLegislative materials.$2lcgft
615  0$aDrug development$xEconomic aspects
615  0$aBuprenorphine$xTherapeutic use
615  0$aOrphan drugs$xGovernment policy
615  0$aDrugs$xPrices$xGovernment policy
615  0$aDrugs$xLaw and legislation
615  0$aOrphan drugs
615  0$aRare diseases
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910715017103321
996   $aFairness in Orphan Drug Exclusivity Act$93527578
997   $aUNINA

LEADER 01786nam0 22003973i 450 
001 UBO3116662
005 20251003044423.0
010   $a019921719X
010   $a9780199217199
100   $a20230719d2007    ||||0itac50      ba
101 | $aeng
102   $agb
181  1$6z01$ai $bxxxe  
182  1$6z01$an
183  1$6z01$anc$2RDAcarrier
200 1 $aEnergy law in Europe$enational, EU, and international regulation$fedited by M. Roggenkamp ... [et al.] - 2. ed
210   $aOxford$cOxford university press$d2007
215   $aCXXI, 1488 p.$d26 cm.
606   $aFonti energetiche$xLegislazione$xEuropa$2FIR$3NAPC258406$9I
676   $a343.4092$9DIRITTO E CONTROLLO DELL'APPROVVIGIONAMENTO IDRICO ED ENERGETICO. Europa$v23
676   $a346.404679$9CONTROLLO E REGOLAMENTAZIONE PUBBLICA DELL'ENERGIA E DELLE RISORSE ENERGETICHE. Europa$v22
696   $aFonti d'energia$aRisorse energetiche$aFonti di energia$aSorgenti d'energia$aSorgenti di energia
699   $aFonti energetiche$yFonti d'energia
699   $aFonti energetiche$yRisorse energetiche
699   $aFonti energetiche$yFonti di energia
699   $aFonti energetiche$ySorgenti d'energia
699   $aFonti energetiche$ySorgenti di energia
702  1$aRoggenkamp$b, Martha M.$3RMSV052544
801  3$aIT$bIT-000000$c20230719
850   $aIT-BN0095          
901   $bNAP 01$cTEDASS    $nex Centro interdipartimentale sulle alte tecnologie per la diagnostica ambientale e lo sviluppo sostenibile
912   $aUBO3116662
950  0$aBiblioteca Centralizzata di Ateneo$b1 v.$c1 v.$d 01TEDASS    346.404679              ENELIE$e 0102 0000090315  VMA FD                    1 v.$fY $h20111114$i20111115
977   $a 01
996   $aEnergy law in europe$9770279
997   $aUNISANNIO